Life sciences advisory
Scientific potential, connected to a path forward.
The challenge
Great science creates potential. The right decisions turn it into value.
Biotech companies face connected decisions around development strategy, value creation, financing, partnering and organisational readiness. Addressed independently, those decisions can dilute momentum and investment confidence.
Accelero connects these decisions into one coherent path to value.
Why Accelero
One senior team. From strategy to execution.
Integrated Perspective
Science, strategy, capital, partnerships and organisational execution are considered together.
Senior Expertise
Clients work directly with experienced senior advisers rather than large junior consulting teams.
Relevant Access
Established international access to investors, industry partners and life sciences decision-makers.
Accountability Through Execution
Support continues beyond recommendations through financing, partnering and implementation.
Clearer priorities. Stronger investment cases. Relevant access. Faster execution.
Who we work with
The decisions behind a stronger path to value.
Biotech & Life Sciences Companies
From early development through clinical scale-up and commercialisation.
Investors
Supporting assessment, value creation and portfolio development.
Industry Partners
Supporting strategic opportunities, licensing and collaboration.
What we do
From scientific potential to enterprise value.
01
Define the path to value.
Translate scientific potential into a focused value creation strategy — from asset priorities and development choices to market positioning and value inflection points.
02
Finance and partner the path.
Build an investment and partnering proposition that brings the right logic, evidence and access together — supported by a long-standing global investor and industry network.
03
Deliver the path.
Align leadership, governance and organisational capabilities so critical decisions turn into funded action, progress and scale.
How we work
A path shaped around the decisions that matter.
We start by identifying the decisions and milestones that create the greatest enterprise value. Those priorities become a strategic roadmap, a credible investment or partnering proposition, and an executable plan.
Understand
Prioritise
Position
Finance / Partner
Execute
Selected impact
Evidence that needs to hold up.
€800M+
Transactions advised
25+
Licensing & partnering transactions supported
30+
Transformations guided
12
years in business
Case studies
SERIES A / CLINICAL ENTRY
Securing Series A Capital for an Oncology Asset
Challenge — A European preclinical biotech needed capital to bring its oncology platform into Phase I.
Accelero Approach — Defined the Target Product Profile and development path; built the investment case and connected the company with relevant European investors.
Result — €18.5M Series A closed, securing runway for clinical validation.
SERIES B / CLINICAL SCALE-UP
Positioning an Immunology Pipeline for Institutional Growth
Challenge — A clinical-stage biotech needed growth capital to advance its immunology pipeline.
Accelero Approach — Sharpened the value proposition, aligned development priorities and positioned the financing process for institutional investors.
Result — Institutional growth financing secured for the next clinical development stage.
LICENSING / STRATEGIC PARTNERSHIP
Creating a Partnering Path for a Clinical-Stage Asset
Challenge — A clinical-stage biotech needed a partnering path that preserved value and flexibility.
Accelero Approach — Defined the asset proposition and deal rationale; engaged relevant pharmaceutical partners and supported negotiations.
Result — $20M upfront payment secured, with up to $400M for each additional indication.
Senior expertise where it matters.
Detlef Krawinkel
Lead · Value & Capital
What creates value and how do we finance it?
Value Strategy · Enterprise Value · Capital Raise · Investor Connectivity · Strategic Relationships
Dr. Barbara Troup
Lead · Strategy & Transformation
What must the organization do to deliver it?
Enterprise Strategy · Leadership · Organization · Governance · Transformation · Execution
Critical Value Decision
From enterprise value to organizational reality.
Value Strategy & Capital
From critical value decision → investment case → investor access → capital raise
Strategy & Transformation
From strategic choice → leadership alignment → transformation → execution
Backed by senior advisors with deep life sciences expertise
Dr. Peter Stangier
Finance & Forecasting
Bertrand Bonnot
Market Data & Development
Dr. Peter Schiemann
Regulatory & Manufacturing
Beat Widler
Safety, Quality & PV
Edward Gudaitis
Commercial
Ruben Giorgino
Pre- & Clinical Development
Our advisers bring experience across biotech, pharma, investing, transactions, commercialisation, development and organisational leadership — and remain directly involved in client work.
Start a conversation
What is your next critical value decision?
Whether you are defining development strategy, preparing for financing, evaluating a licensing opportunity or building for the next stage, we would be pleased to discuss the path ahead.
Basel, Switzerland · International reach
E-mail: d.krawinkel@accelerogmbh.com
Phone: +41 79 925 1535
